Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia.
Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia.
复制标题
探讨影响急性髓系白血病诱导治疗医院费用的决定因素。
DOI：
10.1080/10428194.2020.1855339
复制
发表时间：
2020
影响因子：
2.6
通讯作者：
Que Yimei
中科院分区：
文献类型：
--
作者：
Ning Liqing;Li Dengju;Lu Pingfan;Que Yimei
急性髓性白血病（AML）患者的经济负担是巨大的。我们回顾性分析了我院2013年1月至2018年12月收治的353例初诊AML患者首次诱导治疗的住院费用。我们发现平均住院费用估计为110，291.8元人民币。多因素分析显示，住院时间是影响住院费用的主要因素（p< 0.0001），其次是粒细胞缺乏天数（p< 0.01），但对于未能达到完全缓解（CR）的患者，住院时间是影响住院费用的独立因素。此外，达到CR的患者与未达到CR的患者的住院费用相似。低强度化疗的住院费用可能不低于强化化疗。
The financial burden of acute myeloid leukemia (AML) patients is substantial. We retrospectively analyzed the hospital costs of the first induction therapy for 353 newly diagnosed AML patients who were admitted to our hospital from January 2013 to December 2018. We found the median hospital costs were estimated at 110,291.8 RMB. Multivariate analysis showed that length of hospital stay was the leading determinant affecting hospital costs (p< 0.0001), followed by length of agranulocytosis days (p< 0.01), but for the patients who failed to achieve complete remission (CR), length of hospital stay was the independent factor contributing to hospital costs. Besides, patients achieving CR had similar hospital costs to the patients failing to achieve CR. The hospital costs of low-intensity chemotherapy might not be lower than that of intensive chemotherapy.